Table 1.
Change in MRI parameters from baseline to Year 3 (pooled treatment groups)
| MRI Parameter | ||||||
| T2 lesions | T1 Gd+ lesions | T1 black holes | ||||
| Lesion volume, mm3 | Baseline | Year 3 | Baseline | Year 3 | Baseline | Year 3 |
| N | 158 | 158 | 154 | 154 | 156 | 156 |
| Mean (SD) | 5990.1 (7111.6) | 5345.9 (6755.3) | 73.8 (252.1) | 25.6 (125.5) | 1263.1 (2430.6) | 1185.4 (2520.7) |
| Median | 3378.5 | 2825.0 | 0.0 | 0.0 | 436.3 | 341.9 |
| Q1, Q3 | 1052.9, 7358.5 | 782.0, 6918.5 | 0.0, 0.0 | 0.0, 0.0 | 76.5, 1189.2 | 67.9, 1160.0 |
| Absolute change, mm3 | ||||||
| N | 158 | 154 | 156 | |||
| Mean (SD) | −644.2 (3072.1) | −48.2 (269.3)* | −77.7 (1056.8) | |||
| Median | −135.6 | 0.0 | 0.0 | |||
| Q1, Q3 | −719.8, 86.7 | 0.0, 0.0 | −89.5, 73.4 | |||
| Percentage change† | ||||||
| N | 158 | 34 | 132 | |||
| Mean (SD) | −7.6 (34.1)c | −60.5 (149.4)‡ | 0.3 (67.8) | |||
| Median | −7.3 | −100.0 | −4.7 | |||
| Q1, Q3 | −23.8, 4.0 | −100.0, −100.0 | −32.1, 19.5 | |||
Gd+, gadolinium-enhancing; IFN, interferon.
*P = 0.0034 vs baseline; Wilcoxon signed rank test.
†Percentage change was not calculated for patients with a lesion volume of 0 mm3 at baseline.
‡P < 0.0001 vs baseline; Wilcoxon signed rank test.